UNIVERSAL BIOCELLS PTE. LTD.

Production and R&D Base

GLORY INTELLIGENCE BIO DEVELOPMENT KOREA LAB FUNDATION
Specialized in cell/telomere/gene editing/cloning biolaboratory
From laboratory-scale testing to industrial large-scale production with 10 bioreactors of 4000 liters each. Advanced control
Includes precise monitoring and control systems to optimize culture conditions, with diverse applications: pharmaceuticals, bioproduction, undifferentiated embryonic stem cell research, etc. Real-time tracking of key parameters, including pH value, O2, CO2, NO, foam level, and temperature sensors, to achieve optimal bioprocessing conditions. This meticulous cultivation process ensures the best conditions for the growth and development of cloned cells.

Leveraging Australia's stringent TGA certification system and its advantages of a pure natural ecology, we have built a closed-loop whole industry chain from top-tier research and development to large-scale production. Equipped with world-class research laboratories, we bring together senior experts in the fields of biomedicine, nutrition, and cosmeceutical formulations, focusing on core technological innovations in pharmaceuticals, health products, and cosmeceuticals, and conducting ingredient screening and efficacy verification in accordance with clinical-grade standards. Supported by a modern intelligent production factory, we realize full-process automated control from raw material extraction, formula preparation to finished product filling, strictly adhering to GMP production standards to ensure the purity, activity, and safety of each product. By virtue of the integrated advantages of "research and development - production - quality control", we provide high-quality health products that combine technological strength and natural heritage for the global market.

About US

Universal Biocells Pte., Ltd.
Universal Biocells (China) Ltd is a wholly-owned subsidiary of Singapore - Universal Biocells Pte., Ltd, invested by British Cayman Islands - Universal Biocells Holding Inc. with a registered capital of 10 million yuan, and settled in Xiangjiang New Area in December 2025. The company mainly engages in cross-border sales of daily necessities, cosmetics, health food, etc., providing comprehensive cross-border e-commerce solutions such as global logistics, warehousing, and payment, covering B2B and B2C models, and deeply cultivating markets in Europe, America, Southeast Asia, and other regions. We plan to build a production base by the end of 2026, focusing on areas such as gene editing and industrialization of cell culture. Adhering to the concept of "excellent quality, favorable price", we aim to link global biotechnology resources and achieve two-way circulation of high-quality goods from China and abroad.

ADDRESS ：7500A BEACH ROAD, #04-307, THEPLAZA,SINGAPORE 199591

Email: Service@universalbiocells.com